PANACEABIO

Panacea Biotec Limited

Panacea Biotec Limited (PANACEABIO) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

panaceabiotec.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹359.70
Market cap
2,205 Cr
Stock P/E
Loss (TTM EPS ₹-1.16)
P/B
2.66
ROE (FY26)
-0.6%
ROCE (FY26)
-0.2%
Operating margin (FY26)
-5.9%
Debt / equity (FY26)
0.03
OCF / EBITDA (3Y)
-34.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Panacea Biotec develops and makes vaccines, sold mostly to customers outside India, and sells pharmaceutical formulations and nutrition products in India and overseas.

Company snapshot

75thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 66.3% of revenue

SegmentRevenue shareRevenuePBTAssets
Formulations
33.7%
55 Cr-8 Cr421 Cr
Vaccines
66.3%
108 Cr12 Cr791 Cr

What we see

Positives
  • ✓Debt-to-equity of 0.03x — the company is largely funded by its own money, not borrowed funds.
Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales143 Cr151 Cr136 Cr116 Cr147 Cr163 Cr133 Cr167 Cr141 Cr165 Cr167 Cr200 Cr
Operating expenses (approx.)147 Cr151 Cr143 Cr130 Cr140 Cr156 Cr159 Cr168 Cr159 Cr153 Cr164 Cr194 Cr
EBITDA-4 Cr-0.15 Cr-6 Cr-14 Cr7 Cr8 Cr-27 Cr-1 Cr-18 Cr12 Cr3 Cr6 Cr
OPM %-2.5%-0.1%-4.4%-12.1%4.8%4.9%-20.3%-0.7%-12.6%7.1%1.5%2.8%
Other income3 Cr6 Cr11 Cr4 Cr5 Cr4 Cr9 Cr6 Cr6 Cr2 Cr3 Cr4 Cr
Interest0.91 Cr0.85 Cr0.82 Cr0.87 Cr0.98 Cr0.99 Cr1 Cr0.86 Cr2 Cr2 Cr1 Cr1 Cr
Depreciation9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr8 Cr8 Cr8 Cr8 Cr8 Cr8 Cr
Profit before tax-8 Cr-2 Cr-2 Cr-17 Cr5 Cr4 Cr-0.04 Cr7 Cr-19 Cr6 Cr-1 Cr4 Cr
Tax %-6.6%-33.3%6.1%6.9%1.1%-1.4%-4875.0%39.6%26.9%40.1%20.0%38.4%
Net profit-8 Cr-2 Cr-2 Cr-16 Cr5 Cr4 Cr-2 Cr4 Cr-14 Cr4 Cr-1 Cr2 Cr
EPS (₹)₹-1.35₹-0.37₹-0.23₹-2.59₹0.77₹0.74₹-0.31₹0.66₹-2.27₹0.65₹0.08₹0.38

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales——457 Cr544 Cr625 Cr661 Cr460 Cr559 Cr559 Cr640 CrSign in free for the trailing twelve months
Operating expenses (approx.)——588 Cr513 Cr548 Cr675 Cr558 Cr579 Cr585 Cr644 CrSign in free for the trailing twelve months
EBITDA——-131 Cr31 Cr77 Cr-14 Cr-98 Cr-20 Cr-26 Cr-5 CrSign in free for the trailing twelve months
OPM %——-28.7%5.8%12.3%-2.1%-21.3%-3.6%-4.6%-0.7%Sign in free for the trailing twelve months
Other income——4 Cr30 Cr10 Cr11 Cr52 Cr26 Cr21 Cr17 CrSign in free for the trailing twelve months
Interest——105 Cr174 Cr185 Cr181 Cr4 Cr4 Cr4 Cr6 CrSign in free for the trailing twelve months
Depreciation——54 Cr43 Cr46 Cr44 Cr39 Cr37 Cr35 Cr33 CrSign in free for the trailing twelve months
Profit before tax——49 Cr-177 Cr-145 Cr1,449 Cr13 Cr1 Cr-8 Cr-7 CrSign in free for the trailing twelve months
Tax %——15.9%-9.6%-1.8%25.6%363.7%201.4%-9.7%2.8%Sign in free for the trailing twelve months
Net profit——38 Cr-194 Cr-148 Cr1,078 Cr-34 Cr-1 Cr-9 Cr-7 CrSign in free for the trailing twelve months
EPS (₹)——₹6.15₹-31.72₹-24.11₹175.98₹-5.51₹-0.19₹-1.37₹-0.88Sign in free for the trailing twelve months
Dividend payout %—————0.0%————Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital6 Cr6 Cr6 Cr6 Cr6 Cr6 Cr6 Cr6 Cr6 Cr6 Cr
Reserves350 Cr303 Cr344 Cr193 Cr-235 Cr843 Cr837 Cr836 Cr829 Cr829 Cr
Borrowings905 Cr736 Cr116 Cr617 Cr735 Cr34 Cr20 Cr21 Cr22 Cr24 Cr
Other liabilities529 Cr566 Cr913 Cr578 Cr675 Cr903 Cr411 Cr381 Cr437 Cr410 Cr
Total liabilities1,800 Cr1,608 Cr1,376 Cr1,390 Cr1,179 Cr1,783 Cr1,271 Cr1,241 Cr1,290 Cr1,262 Cr
Fixed assets (net)994 Cr943 Cr803 Cr656 Cr607 Cr588 Cr588 Cr560 Cr543 Cr553 Cr
CWIP9 Cr8 Cr8 Cr10 Cr21 Cr5 Cr28 Cr75 Cr94 Cr100 Cr
Investments2 Cr2 Cr5 Cr6 Cr0.07 Cr5 Cr13 Cr53 Cr19 Cr26 Cr
Loans & advances———4 Cr4 Cr1 Cr2 Cr3 Cr3 Cr2 Cr
Inventories316 Cr334 Cr81 Cr148 Cr174 Cr213 Cr202 Cr178 Cr214 Cr193 Cr
Trade receivables142 Cr136 Cr89 Cr69 Cr85 Cr132 Cr60 Cr57 Cr73 Cr74 Cr
Cash & bank9 Cr16 Cr14 Cr40 Cr52 Cr50 Cr40 Cr47 Cr82 Cr57 Cr
Other assets329 Cr168 Cr374 Cr459 Cr236 Cr789 Cr338 Cr267 Cr263 Cr258 Cr
Total assets1,800 Cr1,608 Cr1,376 Cr1,390 Cr1,179 Cr1,783 Cr1,271 Cr1,241 Cr1,290 Cr1,262 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity131 Cr118 Cr105 Cr-30 Cr107 Cr-108 Cr-423 Cr-0.10 Cr-27 Cr17 Cr
Cash from investing-26 Cr55 Cr-5 Cr-35 Cr-48 Cr1,283 Cr430 Cr10 Cr65 Cr-40 Cr
Cash from financing-107 Cr-164 Cr-101 Cr91 Cr-47 Cr-1,176 Cr-18 Cr-3 Cr-3 Cr-1 Cr
Net cash flow-2 Cr9 Cr-2 Cr26 Cr12 Cr-2 Cr-11 Cr7 Cr35 Cr-25 Cr
Free cash flow (OCF − Capex)107 Cr103 Cr100 Cr-37 Cr85 Cr-121 Cr-464 Cr-78 Cr-78 Cr-37 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %——33.1%-0.4%6.2%185.2%2.0%0.6%-0.5%-0.2%
ROE %——10.9%-99.3%—127.4%-4.0%-0.1%-1.0%-0.6%
Debtor days——7146497248374742
Inventory days——235301376275349309363242
Days payable——780405480336306267384238
Cash conversion cycle——-474-58-541290802746
OCF / EBITDA %———-97.2%139.3%—————
OCF / EBITDA % (3 years)—————-34.1%————
Debt / equity2.542.410.333.15—0.040.020.030.030.03
Current ratio0.910.810.270.861.111.251.711.571.491.47
Net debt / EBITDA———18.388.91—————